The Cardiac Amyloidosis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Cardiac Amyloidosis Market?
The cardiac amyloidosis market size showed robust growth in past years. The market was valued at $5.26 billion in 2024 and is expected to rise to $5.75 billion in 2025. The compound annual growth rate (CAGR) during this period is projected to be 9.2%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Cardiac Amyloidosis Industry?
The Cardiac Amyloidosis Global Market is projected to reach a size of $8.10 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.0%.
Download Your Free Sample of the 2025 Cardiac Amyloidosis Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Cardiac Amyloidosis Market?
The key drivers in the cardiac amyloidosis market are:
• Increase in diagnosis rates of cardiac amyloidosis
• Government support and initiatives towards cardiac amyloidosis treatment
• Rising prevalence of genetic mutations causing cardiac amyloidosis
• Implementation and expansion of patient assistance programs.
Global Market Segmentation: Identifying Major Cardiac Amyloidosis Industry Segments
The cardiac amyloidosis market covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)
Pre-order the 2025 Cardiac Amyloidosis Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Cardiac Amyloidosis Market?
The key trends in the cardiac amyloidosis market are:
• Development of new therapies is a major emerging trend in the cardiac amyloidosis market.
• There is an expanding focus on research in gene therapy.
• Precision medicine is becoming a pivotal focus in this market.
• Advancements in diagnostic technologies and the development of novel therapies are significantly shaping the future of the market.
Who Are the Top Competitors & Leading Players in the Cardiac Amyloidosis Market?
Major players in the cardiac amyloidosis market are:
• Pfizer Inc.
• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Alexion Pharmaceuticals Inc.
• Dr. Reddy’s Laboratories
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc.
• BridgeBio Pharma Inc.
• Prothena Corp
• Intellia Therapeutics Inc.
• Amylyx Pharmaceuticals
• Neurimmune AG
• SOM Biotech
• Oncopeptides
• Attralus Inc.
• Eidos Therapeutics.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the cardiac amyloidosis market in 2024
